Increases in intracellular calcium perturb blood–brain barrier via protein kinase C-alpha and apoptosis  by Rakkar, Kamini & Bayraktutan, Ulvi
Biochimica et Biophysica Acta 1862 (2016) 56–71
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isIncreases in intracellular calcium perturb blood–brain barrier via protein
kinase C-alpha and apoptosisKamini Rakkar, Ulvi Bayraktutan ⁎
Stroke, Division of Clinical Neuroscience, Clinical Sciences Building, School of Medicine, Hucknall Road, Nottingham, NG5 1PB, UKAbbreviations: BAPTA-AM, N,N’-[1,2-ethanediylbis(
[(acetyloxy)methoxy]-2-oxoethyl]]-, bis[(acetyloxy)m
barrier; BSA, bovine serum albumin; BBMEC, bovine br
cells; CNS, central nervous system; EBA, Evan's blue albu
HBSS, Hank's Balanced Salt Solution; HA, human astr
microvascular endothelial cells; IP3, inositol-1,4,5-tripho
oxygen–glucose deprivation with/out reperfusion; PBS, p
protein kinase C; PMA, phorbol-12-myristate-13-acetate
siRNA, small interfering RNA; NaF, sodium ﬂuorescein
tissue plasminogen activator; TEER, transendothelial elect
plasminogen activator.
⁎ Corresponding author.
E-mail address: ulvi.bayraktutan@nottingham.ac.uk (U
http://dx.doi.org/10.1016/j.bbadis.2015.10.016
0925-4439/© Elsevier B.V. All rights reserved.2015a b s t r a c ta r t i c l e i n f oArticle history:
Received 12 May 2015
Received in revised form 14 October 2015
Accepted 20 October 2015
Available online 23 October 2015
Keywords:
Apoptosis
Blood–brain barrier
Intracellular calcium
NADPH oxidase
Protein kinase C
UrokinaseAn increase in intracellular calcium represents one of the early events during an ischaemic stroke. It triggers
many downstream processes which promote the formation of brain oedema, the leading cause of death after
an ischaemic stroke. As impairment of blood–brain barrier (BBB) accounts for much of oedema formation, the
current study explored the impact of intracellular calcium on barrier integrity in relation to protein kinase C,
caspase-3/7, plasminogen activators and the pro-oxidant enzyme NADPH oxidase. Human brain microvascular
endothelial cells alone or in co-culture with human astrocytes were subjected to 4 h of oxygen–glucose depriva-
tion alone or followed by 20 h of reperfusion (OGD ± R) in the absence or presence of inhibitors for urokinase
plasminogen activator (amiloride), NADPH oxidase (apocynin), intracellular calcium (BAPTA-AM) and protein
kinase C-α (RO-32-0432). Endothelial cells with protein kinase C-α knockdown, achieved by siRNA, were also
exposed to the above conditions. BBB permeability was measured by transendothelial electrical resistance and
Evan's blue-albumin and sodium ﬂuorescein ﬂux. Intracellular calcium and total superoxide anion levels,
caspase-3/7, NADPH oxidase, plasminogen activator and protein kinase C activities, stress ﬁbre formation, the
rate of apoptosis and BBB permeability were increased by OGD ± R. Treatment with the speciﬁc inhibitors or
knockdown of protein kinase C-α attenuated them. This study reveals successive increases in intracellular calci-
um levels and protein kinase C-α activity are keymechanisms inOGD±R-mediated impairment of BBB. Further-
more inhibition of protein kinase C-α may be therapeutic in restoring BBB function by reducing the rate of
cytoskeletal reorganisation, oxidative stress and apoptosis.
© Elsevier B.V. All rights reserved.20151. Introduction
The blood–brain barrier (BBB) is composed of tightly packed endo-
thelial cells surrounded by astrocytic endfeet, a basement membrane,
pericytes and neurones. It regulates the passage of circulatingmolecules
into the brain, maintaining central nervous system (CNS) homeostasis.
Hence, any pathology capable of affecting BBB integritywould have dra-
matic consequences for the CNS [1]. During an ischaemic stroke, affect-
ed cells experience an intracellular calcium overload due to depletion ofoxy-2,1-phenylene)]bis[N-[2-
ethyl] ester; BBB, blood–brain
ain microvascular endothelial
min; FBS, foetal bovine serum;
ocytes; HBMEC, human brain
sphate; N, normoxia; OGD ± R,
hosphate buffered saline; PKC,
; ROS, reactive oxygen species;
; O2•−, superoxide anion; tPA,
rical resistance; uPA, urokinase
. Bayraktutan).ATP and subsequent ion pumpdysregulationwhich result in calcium in-
ﬂux. This increase in intracellular calcium is recognised as one of the
ﬁrst mechanisms that ultimately compromise BBB during an ischaemic
stroke. However, the precisemolecular targets and cascade of events re-
main vague. Since calcium is a second messenger and can trigger vari-
ous signalling pathways depending on its speciﬁc localisation within a
cell [2,3] its potential to inﬂuence deleterious processes is vast. Further-
more the effect of increasing intracellular calcium can be two-fold; the
immediate effect of direct interaction of calcium with proteins and
less rapid events which involve changes in gene expression which can
be achieved through signal transduction pathways [4].
Calcium overload has also been associated with cell death during
ischaemic stroke both via apoptosis and necrosis [5]. The apoptotic
pathway can be triggered by many protein cascades and results in
caspase-3/7 activation. Many in vitro and in vivo studies have shown
caspases to become activated during ischaemia/reperfusion [6–8] and
inhibition of caspases with carbobenzoxy-valyl-alanyl-aspartyl-[O-
methyl]-ﬂuoromethylketone has been shown to have beneﬁcial effects
in reducing infarct volumes, tight junction disruption and BBB perme-
ability [9–12].
BBB permeability is predominantly governed by the tight junctions
between adjacent cells and both low and high levels of calcium have
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tions. Increasing intracellular calcium concentrations has been shown
to interfere in tight junction development [13], and lowering calcium
levels have been observed to change the cellular localisation of occludin
and zonula occluden-actin binding [14]. Furthermore in bovine brain
microvascular endothelial cells (BBMEC) exposed to hypoxia–
aglycaemia and treated with a calcium channel blocker SKF 96365,
occludin cellular localisation and BBB permeability was partially
protected [15]. Therefore the ability of endothelial cells to maintain a
balance in calcium concentration is vital to their ability to maintain
BBB integrity.
Many studies have shown calcium to be a key governor in BBB per-
meability. In BBMEC cultured with rat astroglioma cells BBB permeabil-
itywas increased after hypoxia–aglycaemiawhichwas ameliorated by a
calcium channel blocker nifedipine indicating the role of calcium ﬂux in
BBB permeability [16]. Furthermore in porcine endotheial cells nifedi-
pine also reduced the increase in ischaemia-induced BBB permeability
and evidence was provided that blockage of protein kinase C (PKC)
translocation to the membrane played a part [17]. In BBMEC intracellu-
lar calcium levels were increased after hypoxia/reoxygenation although
capacitive calcium entry was inhibited. Furthermore the increase was
blocked by superoxide dismutase and inhibitors of mitochondrial elec-
tron transport, indicating the role of reactive oxygen species (ROS) in
calcium signalling [18].
Calcium regulates many downstream processes such as protein
phosphorylation (through PKC) and ROS generation, both of which
can regulate protein activity and have been implicated in BBB damage
during ischaemic stroke. Conventional (calcium-dependent) PKC iso-
forms are therefore a key focus in BBB permeability especially since
they have been found to be upregulated in hyperglycaemic and ischae-
mic conditions. In BBMEC, hypoxia/aglycaemia induced expressions of
membrane-bound PKC-α and -βI, [19]. In cultured porcine endothelial
cells, ischaemia induced increases in PKC and inhibition of PKC-α re-
duced endothelial permeability [17] and in rat brain microvessel endo-
thelial cells total PKC activity was increased after hypoxia [20]. PKC is
also known to affect cell morphology by activating endothelial contrac-
tion [21] which alters adherens and tight junctions and thus evoke BBB
permeability [22]. Recent studies have also shownPKC and ROS to be in-
volved in BBB damage under hyperglycaemic conditions. In human
brainmicrovascular endothelial cells (HBMEC) hyperglycaemia induced
BBB permeability appeared to bemediated by PKC and subsequent acti-
vation of nicotinamide adenine dinucleotide phosphate (NADPH) oxi-
dase activity which elevated total superoxide anion (O2•−) levels and
therefore oxidative stress [23,24]. Similar ﬁndings have also been re-
ported in bovine vascular endothelial cells [25].
Another element of BBB hyperpermeability during ischaemic stroke
is the increased damage observed during reperfusion which can lead to
vasogenic brain oedema. During reperfusion there is a substantial in-
crease in oxidative stress which contributes to BBB impairment [26,
27]. Many studies suggest that increases in ROS levels disrupt endothe-
lial tight junctions, resulting in increased BBB permeability [28–30].
Studies have also shown NADPH oxidase to be involved in reperfusion
injury [31–33] for example in an immortalised Lewis rat cell line, O2•−
has been shown to disrupt tight junctions and induce F-actin polymer-
isation into stress ﬁbres [34].
Endogenous reperfusion is achieved through the activation of the
plasminogen-plasmin system and in particular tissue plasminogen acti-
vator (tPA) and urokinase plasminogen activator (uPA). Both these ser-
ine proteases cleave plasminogen to form plasminwhich then degrades
the ﬁbrinous blood clot, restoring blood ﬂow to the occluded vessel and
downstream tissue. tPA and uPA have been studied well under ischae-
mic conditions [35,36]. The literature however is undecided as to
whether these serine proteases are beneﬁcial or damaging [37,38].
Our previous study has shown both tPA and uPA activities to be upreg-
ulated during in vitro ischaemia-reperfusion settings and more perti-
nently to be regulated by ROS [33]. However this area remains largelyunexplored and even less well studied, is the link between plasminogen
activators and intracellular calcium.
A few studies have shown that tPA can cleave the N-methyl-D-
aspartate receptor and induce calcium inﬂux in neurones [39,40], how-
ever studies in endothelial cells are lacking. tPA has also been shown to
have both an apoptotic and anti-apoptotic effect on cortical neurones
[41,42]. Studies in human umbilical vein endothelial cells have shown
PKC to regulate uPA by upregulating expression of the uPA receptor
[43–45]. Some studies have shown the role of uPA in apoptosis in gan-
glion cells [46] and kidney allograft rejection [47], however studies
looking at the BBB are needed.
This study explores the link between calcium-induced signalling
cascades such as PKC activation and their role in ROS generation and
BBB damage. Additionally this study attempts to take this link further
by looking at cell apoptosis, stress ﬁbre formation and plasminogen ac-
tivator activities under oxygen–glucose deprivation with/out reperfu-
sion (OGD ± R).
2. Materials and methods
2.1. Cell culture and OGD ± R experiments
HBMECwere purchased from ScienCell and grown to subconﬂuence
in its specialised media (containing 10% FBS) before exposure to OGD
(94.5% N2, 0.5% O2 and 5% CO2) or normoxia (75% N2, 20% O2 and 5%
CO2) for 0.5 to 4 h. These OGD conditions were used to mimic a severe
ischaemic attack. In some experiments, OGDwas followed by 20 h of re-
perfusion in which the RPMI media (ischaemic culture medium lacking
glucose, pyruvate and foetal bovine serum (FBS), Sigma) was replaced
with fresh HBMEC cell media containing 5.5 mM glucose and 10% FBS
before exposing cells to normoxic conditions. In other experiments,
amiloride (uPA inhibitor, 2.5 μM, Sigma), apocynin (NADPH oxidase in-
hibitor, 1 mM, Sigma), BAPTA-AM (intracellular calcium chelator,
10 μM, Merck), bisindolylmaleimide (PKC inhibitor, 5 μM, Calbiochem),
LY-333,531 (PKC-β inhibitor, 1 μM, Enzo Life Sciences), CGP-53,353
(PKC-βII inhibitor, 1 μM, Calbiochem) or RO-32-0432 (PKC-α inhibitor,
1 μM, Calbiochem) was also added to culture media during OGD or re-
perfusion stages. In other experiments, normoxic HBMECwere exposed
to phorbol-12-myristate-13-acetate (PMA, a PKC activator, 0.1 μM,
Sigma) with/out BAPTA-AM.
2.2. In vitro model of human BBB
Human astrocytes (HA) were purchased from ScienCell and seeded
onto the outer surface of untreated polyester Transwell inserts (0.4 μm
pore, Corning Costar) seated upside down in HA media. The next day,
HBMEC were seeded onto the inner surface of the same inserts in
HBMEC media. Both sets of cells were grown to conﬂuence (~5–6 days)
in their specialised cell media before exposure and/or treatment. The in-
serts provided free ﬂow ofmedia and/or any substances produced by the
HBMEC and HA to encourage BBB development.
2.3. Assessment of BBB permeability
The BBB integrity and function were studied as previously described
[48–51]. Transendothelial electrical resistance (TEER) was measured
using STX electrodes and an EVOM resistance metre (World Precision
Instruments). To measure Evan's blue-labelled albumin (EBA, 67 kDa)
or sodium ﬂuorescein (NaF, 376 Da) ﬂux, inserts were transferred to
new 12-well plates containing 2 mL of Hank's Balanced Salt Solution
(Sigma). EBA (500 μL, 165 μg/mL, Sigma) or NaF (500 μL, 10 μg/mL,
Sigma) was added to the luminal compartments and after 60 min sam-
ples were taken from both abluminal and luminal chambers. The con-
centration of dye in each chamber was determined by measuring the
absorbance (610 nm, EBA) or ﬂuorescence (excitation 485 nm and
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(abluminal reading × 2000 × luminal reading−1).
2.4. Small interfering RNA (siRNA) knockdown
Subconﬂuent cells were transfected with ON-TARGET plus
SMARTpool human PKC-α (50 nM) or non-targeting (50 nM) siRNA
using DharmaFECT transfection reagent 4 (Thermo Scientiﬁc) for 16 h
on day one after which the transfection reagent was replaced with
HBMEC cell media. On day three the transfection was repeated after
which the cells were used in relevant experiments. The sequences of
the oligonucleotides used in PKC-α SMARTpool were: UCACUGCUCU
AUGGACUUA, GAAGGGUUCUCGUAUGUCA, UUAUAGGGAUCUGAAG
UUA and UAAGGAACCACAAGCAGUA.
2.5. Intracellular calcium determination
Intracellular calcium levels were determined using the Fluo-4 NW
Calcium Assay kit (Invitrogen). Brieﬂy, cells grown in opaque black 96
well plates (Nunc) were incubated with dye loading solution for
45 min to load cells with Fluo-4 AM, an indicator for intracellular calci-
um. This solution was then removed, the cells washed once with phos-
phate buffered saline (PBS, Sigma) and then either RPMI or HBMEC
media was added to the wells. Cells were then exposed/treated after
which the ﬂuorescence wasmeasured (excitation 485 nmand emission
520 nm, room temperature) and buffer blanks subtracted.
2.6. Caspase-3/7 activity
Caspase-3/7 activity was determined using the Apo-ONE Homoge-
nous Caspase-3/7 Assay (Promega) as previously documented [52].
Brieﬂy, cells grown in opaque black 96 well plates were exposed or
treated as above after which 100 μL of Apo-ONE Caspase-3/7 reagent
was added to each well and the plates frozen immediately at−80 °C.
After one freeze thaw cycle the ﬂuorescence was measured (excitation
485 nm and emission 520 nm) and buffer blanks subtracted.
2.7. TUNEL staining
To view apoptotic nuclei a DeadEnd Colorimetric TUNEL Systemwas
used (Promega). Brieﬂy, HBMEC were grown on coverslips, exposed/
treated as above and then ﬁxed with 4% paraformaldehyde (Sigma) in
PBS. To enable end-labelling of DNA fragments, coverslipswere incubat-
ed with a recombinant terminal deoxynucleotidyl transferase reaction
mix for 60 min at 37 °C. Incorporated biotinylated nucleotides were de-
tected by horseradish peroxidase-labelled streptavidin and the chromo-
gen diaminobenzidine which stains apoptotic nuclei dark brown.
HBMEC were viewed with a light microscope and average % rate of ap-
optosis calculated from 3 different ﬁelds per coverslip for one indepen-
dent experiment from the following equation: (number of apoptotic
nuclei/total number of nuclei) × 100.
2.8. PKC activity
PKC activity was determined as before using the PepTag Assay for
Non-Radioactive Detection of Protein kinase C (Promega) [53]. Brieﬂy,
cell pellets were sonicated in PKC extraction buffer (containing 0.05%
Triton X-100) to obtain cytosolic andmembranal PKC proteins. The son-
icate was passed through a diethylaminoethyl cellulose column. PKC
samples were incubated with PepTag C1 peptide, a ﬂuorescent sub-
strate, in a PKC reactionmix (containing calcium andphoshatidylserine)
for 30 min at 30 °C. The PKC reaction mix ensured all components
required for PKC activation were present. Samples, including positive
(puriﬁed active rat PKC) and negative (ultra-pure water) controls,
were electrophoresed on a 0.8% agarose gel at 80 V for 45 min and thebands visualised under UV light. Bands were excised and their absor-
bance measured at 570 nm.
For the speciﬁc activities of PKC-α and PKC-βI, the isoforms were
immunoprecipitated using respective primary antibodies (Santa Cruz
Biotechnology) and Dynabeads protein G (Invitrogen) before using
the above assay kit.2.9. tPA and uPA ELISA.
uPA and tPA activities weremeasured using an ELISA-based assay as
previously described [33]. Brieﬂy, 96well plates were coatedwith PAI-1
(300 ng/mL; Abcam) to detect and bind active tPA or uPA. Plates were
then blocked with 3% bovine serum albumin (BSA, Thermo Fischer
Scientiﬁc). Equal volumes of cell culture media or uPA and tPA stan-
dards (Calbiochem) were added to the PAI-1-coated wells and the
plates incubated for 2 h at room temperature. PAI-1-bound active uPA
or tPA was detected by anti-tPA or anti-uPA primary antibodies (1:50,
Santa Cruz Biotechnology) and primary antibodies were probed with
horseradish peroxidase-linked secondary antibodies (1:5000, Santa
Cruz). A colourimetric horseradish peroxidase substrate, 3,3′,5,5′-
tetramethylbenzidine (Thermo Scientiﬁc), was added to thewells to vi-
sualise and quantitate PAI-1-tPA/uPA-antibody complexes. The reaction
was stopped with H2SO4 and absorbances were read immediately at
450 nm and normalised against the respective standards and total pro-
tein concentrations.2.10. total O2
•− production and NADPH oxidase activity
Total O2•– levels were determined using the cytochrome C reduction
assay [48]. Brieﬂy, cell pellets were sonicated in cold lysis buffer con-
taining HEPES buffer (20 mM, pH 7.2, Calbiochem), ethylene glycol
tetraacetic acid (1mM, Sigma), mannitol (210mM, Sigma) and sucrose
(70mM, Sigma). Equal amounts of homogenate (100 μg) were incubat-
ed with cytochrome C (50 μM, Sigma) at 37 °C for 60 min before absor-
bances were measured at 550 nm.
NADPH oxidase activity was measured with the lucigenin chemilu-
minescence assay [51]. Brieﬂy, samples of homogenates (~100 μg)
were processed as above then incubated at 37 °C in assay buffer contain-
ingpotassiumphosphate buffer (50mM, pH7.0, Sigma), ethylene glycol
tetraacetic acid (1mM), sucrose (150mM) and lucigenin (5 μM, Sigma).
The assay buffer also contained the speciﬁc inhibitors for other ROS-
generating enzymes; nitric oxide synthase (NG-nitro-L-argininemethyl
ester, 100 μM, Sigma), mitochondrial complex I (rotenone, 50 μM,
Sigma), xanthine oxidase (allopurinol, 100 μM, Sigma) and cyclooxy-
genase (indomethacin, 50 μM, Sigma). After 15 min, NADPH (100 μM;
Calbiochem) was added to initiate the reaction. The reaction was mon-
itored every minute for 2 h and the rate of reaction calculated. Buffer
blanks were also run for both assays and subtracted from the data.2.11. Western blotting
HBMEC were harvested with 0.1% Triton X-100 (Sigma) in PBS
containing 1 mg/ml aprotinin, 10 mg/ml leupeptin and 1 mM
phenylmethylsulfonyl ﬂuoride. The lysate was centrifuged at
11,500 ×g for 20 min at 4 °C. Protein concentration was quantiﬁed
using the Bradford Protein Assay Kit (Pierce). Protein samples (50 μg)
were run on a 10% SDS-polyacrylamide gels before transferring onto
Hybond-P PVDF membrane (GE healthcare). Membranes were blocked
with 5%milk then exposed to PKC-α (1:500, Santa Cruz Biotechnology)
and β-actin (1:15,000, Sigma) primary antibodies followed by infrared
dye-tagged secondary antibodies (1:30,000, LI-COR Biosciences). The
bands were detected and analysed using the Odyssey Infrared Imaging
System.
Fig. 1. Shorter periods of OGD ± R result in increases in intracellular calcium levels and
caspase-3/7 activity. HBMEC were exposed to 30 mins, 1 h, 2 h or 4 h of OGD alone or
followed by 20 h of reperfusion (R). Intracellular calcium levels (A) and caspase-3/7
activity (B) are increased compared to normoxic cells in all OGD±R conditions. Data rep-
resented asmean± SEM fromn ≥ 4.* P b 0.05 compared to Normoxia. † P b 0.05 compared
to respective OGD group.
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HBMEC grown on coverslips to ~80% conﬂuence were exposed to
experimental conditions before successively ﬁxing, permeabilising and
blocking with 4% paraformaldehyde, 0.1% Triton X-100 and 1% BSA for
20 min each. Cells were stained in the dark with rhodamine phalloidin
dye (20 U/mL, Invitrogen) for 20 min then washed with PBS. Finally
cells were stainedwith DAPI (1 μg/mL) and visualisedwithﬂuorescence
microscopy.
2.13. cell viability
An aliquot of cells were mixed with 0.1% Trypan blue and visualised
under a light microscope. Percentage viability was calculated from
counting 100 cells.
2.14. statistical analyses
Data are presented as mean ± SEM from at least 3 independent ex-
periments. Statistical analyses were performed using one way ANOVA
followed by a Tukey post hoc analysis or, where appropriate, by an inde-
pendent Student's t-test. p b 0.05 was considered as signiﬁcant.
3. Results
3.1. OGD ± R increase intracellular calcium levels, caspase-3/7 activity
and apoptosis
Exposure of HBMEC to OGD (0.5–4 h) alone or followed by 20 h of
reperfusion led to signiﬁcant increases in intracellular calcium levels,
caspase-3/7 activity (Fig. 1A-B) and apoptosis rate as ascertained by
TUNEL staining (Fig. 2A-B), as early as 30 min of OGD. Interestingly,
while reperfusion augmented the increases observed in calcium levels,
it decreased those seen in caspase-3/7 activity and apoptosis rates. As
the impact of 4 h of OGD ± R on the above parameters was slightly
higher, albeit not signiﬁcantly so, this time period was chosen for all
subsequent experiments. It is noteworthy that this timepoint is clinical-
ly relevant [54] and consistent with previous studies [33].
3.2. PKC activity is increased during OGD ± R
To determine the speciﬁc conventional PKC isoform(s) that are af-
fected by ischaemic injury, HBMECwere exposed to OGD±R in the ab-
sence or presence of speciﬁc inhibitors for PKC-α (RO-32-0432) [55],
−β (LY-333,531) [56] and -βII (CGP-53,353) [57]. OGD ± R evoked a
signiﬁcant increase in PKC activity whichwere normalised by inhibition
of total PKC activity with bisindolylmaleimide [58] (Fig. 3A). HBMEC
treated with RO-32-0432 showed equally suppressed PKC activity in
both OGD and reperfusion stages compared to untreated cells. Treat-
ment with LY-333,531 and CGP-53,353 also showed signiﬁcant de-
creases in PKC activity compared to untreated cells however higher
levels of activity were observed during the reperfusion stage compared
to OGD alone (Fig. 3B). To probe PKC-α and -βI activities directly, the
isoforms were immunoprecipitated before performing the PKC activity
assay. The activities of both isoformswere signiﬁcantly increased during
OGD ± R compared to normoxic cells (Fig. 3C-D). Since the use of RO-
32-0432 produced similar levels of total PKC inhibition during both
OGD and reperfusion it would appear that PKC-α activity is the most
consistent during OGD ± R and therefore this isoform was studied fur-
ther in the experiments below.
3.3. BAPTA-AM attenuates the rise in PKC activity during OGD ± R
As conventional PKC isoforms require calcium for their activity [59],
reduction of intracellular calcium in HBMEC with BAPTA-AM [60] ex-
pectedly decreased the OGD ± R-mediated rise in PKC activity(Fig. 3E). To test whether BAPTA-AM had a direct effect on PKC activity,
PMA, a proven PKC activator [61], was used to induce PKC activity. As
expected, PMA signiﬁcantly enhanced PKC activity which was normal-
ised by co-exposure or pre-exposure (4 h) with BAPTA-AM (Fig. 3F).
PMA also markedly increased PKC-α activity (Fig. 3G).
3.4. Inhibition of uPA and NADPH oxidase attenuates OGD ± R-evoked
increases in PKC-α activity
Inhibition of uPA and NADPH oxidase in HBMEC exposed to OGD ±
R normalised the stimulatory effects of both phenomena on total PKC
and PKC-α activities (Fig. 4A–B). However since the uPA inhibitor,
amiloride, has known effects of inhibitingNa+andNa+/H+exchange
channels it is possible these effectsmay also bedue to inhibition of these
channels as well as uPA. To determine the effect of intracellular calcium
and PKC-α on plasminogen activators, the activities of tPA and uPA
were determined in cells subjected to OGD ± R with BAPTA-AM or
RO-32-0432. Similar to a previous study while OGD ± R induced tPA
and uPA activities [33], chelation of intracellular calcium or inhibition
Fig. 2. Shorter periods of OGD±R result in increases the rate of apoptosis. HBMECwere exposed to 30mins, 1 h, 2 h or 4 h of OGD alone or followed by 20 h of reperfusion (R). The rate of
apoptosiswas increased during all OGD±R time points compared to normoxic cells (A). TUNEL staining showed an increase in the number of apoptotic nuclei (dark brown staining) in all
OGD ± R conditions compared to normoxic cells (Bar 50 μm, B). Arrows indicate representative apoptotic nuclei. Data represented as mean ± SEM from n = 4.* P b 0.05 compared to
Normoxia.
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Fig. 3. PKC-α is a key player in increasing total PKC activity during OGD ± R. HBMEC were exposed to 4 h OGD (OGD) with or without reperfusion (R) or a PKC activator PMA.
Bisindolylmaleimide, a general PKC activity inhibitor, normalised the increases in PKC activity seen during OGD ± R (A). Inhibitors for α (Ro-32-0432), β (LY-333,531) and βII (CGP-
53,353) isoforms also show attenuation of increased PKC activity duringOGD±R (B). PKC-α (C) and PKC-βI (D) activities are increased duringOGD±R. Chelation of intracellular calcium
with BAPTA-AM decreased the rise in PKC activity seen during OGD± R (E). PMA increased PKC activity and co-exposure or 4 h pre-exposure with BAPTA-AM normalised the increases
seen (F). Exposure to PMA also increased PKC-α activity (G). Data represented as mean ± SEM from ≥3. * P b 0.05 compared to Normoxia or control. † P b 0.05 compared to respective
untreated group. § P b 0.05 compared to PMA.
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insigniﬁcantly higher compared to normoxic cells with the RO-32-
0432 treatment (Fig. 4C–D).
3.5. Inhibition of PKC-α reduces total O2•− levels andNADPHoxidase activity
To test whether O2•− or NADPH oxidase activity is affected by intra-
cellular calcium, total PKC and PKC-α, HBMEC were exposed to
OGD ± R with or without BAPTA-AM, bisindolylmaleimide or RO-32-
0432. In support of our recent study [33], reperfusion has been shown
to further potentiate the increases observed in total O2•− and NADPH ox-
idase activity evoked by OGD. Although all the aforementioned inhibi-
tors reduced both increases (Fig. 5A-D), the levels still remained
signiﬁcantly higher than normoxic cells with bisindolylmaleimide and
RO-32-0432 treatment. To examine the direct effect of PKC activity,
HBMEC were exposed to PMA which signiﬁcantly increased both totalO2•− levels and NADPH activity where addition of BAPTA-AM reversed
these increases (Fig. 5E-F).
3.6. Rises in calcium levels and caspase-3/7 activity are attenuated by
amiloride, apocynin, BAPTA-AM and RO-32-0432
HBMEC were exposed to OGD ± R and treated with amiloride,
apocynin, BAPTA-AM or RO-32-0432. Amiloride and apocynin signiﬁ-
cantly reduced increases in intracellular calcium levels during reperfu-
sion only whereas BAPTA-AM reduced calcium levels during OGD and
reperfusion. However since amiloride can also inhibit Na + channels
and the Na+/H+ exchanger, it is possible that the above effects are
not entirely due to uPA inhibition. RO-32-0432 signiﬁcantly reduced
calcium levels during both OGD and reperfusion although levels remain
elevated compared to normoxic cells (Fig. 6A). All the inhibitors men-
tioned also signiﬁcantly reduced the increases observed in caspase-3/7
Fig. 4.Amiloride and apocynin reduce PKC activity and uPA activity affected by PKC-α. HBMECwere exposed to 4 h OGD (OGD)with orwithout reperfusion (R) in the absence or presence
of inhibitors for uPA (amiloride), NADPH oxidase (apocynin), intracellular calcium (BAPTA-AM) or PKC-α (RO-32-0432). Amiloride and apocynin decreased the rise in total PKC (A) and
PKC-α (B) activities seen duringOGD±R. tPA activity is increased duringOGD±R and treatmentwith BAPT-AMandRO-32-0432 showno effect (C). uPA activity is also increased during
OGD ± R and BAPTA-AM and RO-32-0432 normalised the increases seen (D). Data represented as mean ± SEM from n ≥ 3.* P b 0.05 compared to Normoxia. † P b 0.05 compared to re-
spective untreated group.
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treated with apocynin and amiloride still remained higher than
normoxic cells during reperfusion (Fig. 6B).3.7. PKC-α silencing reduces OGD ± R-evoked increases in calcium levels,
caspase-3/7 activity and apoptosis rate
To look directly at PKC-α activity and establish results with RO-32-
0432, PKC-α gene expression was silenced using speciﬁc siRNA. PKC-
α knockdown signiﬁcantly reduced PKC-α protein levels compared to
control cells and cells exposed to non-targeting siRNA (Fig. 7). PKC-α
knockdown signiﬁcantly reduced caspase-3/7 activity and the rate of
apoptosis compared to cells exposed to OGD ± R, however the rate
remained signiﬁcantly higher than normoxic cells. TUNEL staining also
showed fewer apoptotic nuclei with PKC-α siRNA compared to NT
siRNA (Fig. 8A-B).3.8. Amiloride, apocynin, BAPTA-AM and RO-32-0432 reduced the rate of
apoptosis during OGD ± R
Toexamine the speciﬁc relevance of uPA, NADPHoxidase, intracellu-
lar calcium and PKC-α to cell viability, HBMEC were exposed to OGD±
R in the presence of their respective inhibitors before viewing apoptotic
nuclei via a TUNEL kit. All inhibitors dramatically reduced the rate of
OGD ± R-mediated apoptosis however the rate remained signiﬁcantly
elevated compared to normoxic cells (Fig. 9).3.9. OGD ± R induces stress ﬁbre formation
HBMEC grown on coverslips were exposed to OGD ± R in the ab-
sence or presence of aforementioned enzyme inhibitors. Cells targeted
with PKC-α siRNA or non-targeting siRNA were also exposed to
OGD ± R. All the above inhibitors and PKC-α siRNA showed reduced
or no stress ﬁbre formation when compared to HBMEC exposed to
OGD ± R alone (Fig. 10).
3.10. Suppression of PKC-α activity protects the BBB during OGD ± R
Ultimately the usefulness of PKC-α inhibition was determined on a
co-culturemodel of the BBB comprised of HBMEC andHA. OGD±R sig-
niﬁcantly increased BBB permeability as observed by decreases in TEER
and increases in EBA and NaF ﬂux. Furthermore, reperfusion showed
signiﬁcantly lower TEER values and higher ﬂux volumes compared to
OGD alone, supporting previous data [33]. Chelation of intracellular cal-
ciumnormalised TEER values and EBA ﬂux volumeswhere NaF volumes
remained signiﬁcantly higher than normoxic cells (Fig. 11A–C). PKC-α
suppression via siRNA also restored BBB permeability as indicated by
signiﬁcant increases in TEER values and reductions in ﬂux volumes
compared to untreated cells (Fig. 11D-F). To determine the effect of
BAPTA-AM and PKC-α siRNA on PKC activity co-cultures were exposed
to PMA before treatment. PMA increased BBB damage which was re-
versed with BAPTA-AM or PKC-α knockdown. Double treatment with
both BAPTA-AM and PKC-α siRNA showed a slight beneﬁt over single
treatment as observed by completely normalised TEER values and
paracellular ﬂux (Fig. 11G–I).
Fig. 5. PKC-α reduces total O2•− levels and NADPH activity. HBMEC were exposed to 4 h OGD (OGD) with or without reperfusion (R) in the absence or presence of inhibitors for PKC
(bisindolylmaleimide), intracellular calcium (BAPTA-AM) or PKC-α (RO-32-0432). HBMEC were also exposed to PMA, a PKC activator, with or without BAPTA-AM treatment. Total O2•−
levels were increased during OGD± R and treatment with bisindolylmaleimide or RO-32-0432 normalised O2•− levels although they remained higher than normoxic cells (A). Treatment
with BAPTA-AM completely normalised the increases observed (B). NADPH oxidase activity followed a similar pattern to that of O2•− levels during OGD ± R (C-D). Exposure to PMA in-
creasedO2•− levels andNADPHoxidase activity and treatmentwith BAPTA-AMabolished these changes (E-F). Data represented asmean±SEM fromn ≥ 3.* P b 0.05 compared toNormoxia
or control. § P b 0.05 compared to 4 h OGD. † P b 0.05 compared to respective untreated group.
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Interruption of blood ﬂow during an ischaemic stroke results in a
cascade of molecular events which elicit BBB damage and may be exac-
erbated during reperfusion [62]. An increase in intracellular calcium is
one of the ﬁrst events which trigger these harmful cellular cascades
and our study shows intracellular calcium to not only be increased as
early as 30 min of OGD but to still be elevated at 20 h of reperfusion
[63,64].
Calcium has been a therapeutic target in ischaemic stroke and calci-
um channel blockers have been shown to have therapeutic relevance in
neurones such asnimodipine, an L-type channel blockerwhichhas been
shown to improve cerebral blood ﬂow and metabolic rates in humans
[65,66]. However not much is known about the role of calcium in BBB
damage. Indeed, there is no ﬁrm proof that clinical outcome after strokeis improved with calcium channel blockers [67,68]. The present study
suggests that chelation of intracellular calcium is an effective therapeu-
tic option in HBMEC and in vitro BBB damage.
As the presence of astrocytes is a prerequisite for appropriate ex-
pression and localisation of endothelial cell tight junction proteins, a
HBMEC-HA contact co-culture model was employed throughout this
study tomeasure BBB permeability [69,70]. Although the normoxic bar-
rier functionmay be considerably lower than in vivo studies, the contact
co-culture model employed in this study has been shown to be one of
the most reliable in vitro models of human BBB in previous studies
[24,48]. Indeed, similar to in vivo settings, the close proximity
(≤10 μM) between endothelial cell and astrocyte layers in thismodel al-
lows cells to effectively communicate with one another and respond to
agents that may be released by the other cell line. This feature of the
contact co-culture model was of particular importance in discovering
Fig. 6. Inhibition of NADPH oxidase, PKC-α, and uPA reduces OGD ± R induced increases
in caspase-3/7 activity and apoptosis rate. HBMECwere exposed to 4 hOGD (OGD)with or
without reperfusion (R) in the absence or presence of inhibitors for uPA (amiloride),
NADPH oxidase (apocynin), intracellular calcium (BAPTA-AM) or PKC-α (RO-32-0432).
Amiloride and apocynin reduced increases in intracellular calcium levels during reperfu-
sion only whereas BAPTA-AM reduced calcium levels during OGD ± R. RO-32-0432 re-
duced calcium levels during OGD ± R although levels remained elevated compared to
normoxic cells especially during OGD (A). Amiloride and apocynin reduced the increase
observed in caspase-3/7 activity during OGD ± R however activity still remained higher
than normoxic cells during reperfusion. Both BAPTA-AM and RO-32-0432 normalised
caspase-3/7 activities during OGD ± R (B). Data represented as mean ± SEM from n ≥ 3.
* P b 0.05 compared to Normoxia. † P b 0.05 compared to respective untreated group.
Fig. 7. Knockdown of PKC-α reduces PKC-α protein levels. PKC-α knockdown reduces
PKC-α protein levels compared to control cells and cells exposed to non-targeting
(NT) siRNA as conﬁrmed by Western blotting. Data represented as mean ± SEM from
n = 4.* P b 0.05 compared to control.
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ing higher rates of astrocytic viability as ascertained by lower apoptosis
rates of astrocytes cultured in endothelial cell conditionedmedium [52].
It is possible that the varying results obtained with calcium antago-
nistsmay be due to their different speciﬁcities for different types of neu-
ronal calcium channels [71] and the different treatment times, where
pre-dosing of the animals was seen to be most effective [72]. More im-
portantly, these antagonists block extracellular calcium from entering
and increasing intracellular calcium levels. Therefore it is likely that cal-
cium released from intracellular sources such as the endoplasmic retic-
ulum and mitochondria can sufﬁciently increase intracellular calcium
levels under stress [73] and affect various downstream signalling path-
ways such as PKC [74]. Therefore the buffering of intracellular calcium
ions may prove to be more effective as shown in the current study.
Our results show that conventional PKC isoforms are predominantly
activated during OGD± R, similar to ﬁndings in other pathologies such
as hyperglycaemia [23,24], with PKC-α inhibition and gene silencing
shown to be an important therapeutic intervention. Additionally chela-
tion of intracellular calcium proved to be a pivotal inhibitory mecha-
nism for PKC, substantiating its role as an initiator of this deleteriouscascade. Indeed, it has been shown that the use of BAPTA, a non-cell per-
meable chelator of calcium, did not affect increases in PKC activity [61]
further supporting the hypothesis that cytosolic calcium triggers signal-
ling cascades detrimental to BBB permeability.
Investigating these ﬁndings deeper, inhibition of PKC-αwith RO-32-
0432 was shown to downregulate OGD ± R-induced uPA activity
whereas calcium-chelation completely normalised it. These results not
only suggest the involvement of other calcium-dependent PKC isoforms
in uPA regulation but also prove the effective inhibition of PKC with
BAPTA-AM. Given that BAPTA-AM is an intracellular calcium chelator,
its inhibitory effects on uPA activity are likely to be more diverse than
the sole inhibition of PKC and to include inhibition or downregulation
of other calcium-dependent cascades. Conversely inhibition of PKC-α
and chelation of intracellular calcium did not affect tPA activity. There-
fore it is possible that tPA may operate upstream to these mechanisms.
The OGD ± R-mediated increases observed in both plasminogen
activator activities were consistent with the present literature [38,75].
Inhibition of uPA by amiloride [76] downregulated both total PKC
and PKC-α activities and thus implied a reciprocal relationship between
uPA and PKC. However since amiloride is known to inhibit Na+/H+
exchange and Na+ channels generally at higher concentrations
(N130 μM), it is possible the effects seen from its use may also be due
to inhibition of these channels. Amiloride has been observed to be a spe-
ciﬁc inhibitor for uPA at lower concentrations such as that used in the
current study [76] however its implications in ion channel inhibition
Fig. 8.Knockdownof PKC-α reduces OGD±R induced increases in caspase-3/7 activity and apoptosis rate. HBMECwere exposed to 4 hOGD (OGD)with orwithout reperfusion (R) in the
absence or presence of PKC-α siRNA. PKC-α knockdown cells reduced caspase-3/7 activity and the rate of apoptosis compared to untreated cells (A and B). TUNEL staining for PKC-α
knockdown cells exposed to OGD± R showed fewer apoptotic nuclei (dark brown staining) compared to NT siRNA treated cells (Bar 50 μm, C). Arrows indicate representative apoptotic
nuclei. Data represented as mean ± SEM from n ≥ 3.* P b 0.05 compared to Normoxia. † P b 0.05 compared to respective untreated group.
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done with caution.
The regulation of uPA activity by PKC is well-documented [43–45]
however the reverse is much less explored. Interaction of uPA with its
receptor may indirectly affect PKC activity viamitogen-activated pro-
tein kinases which despite regulating both uPA and PKC separately
may also be able to connect them [77–79]. Moreover, impairment of
glucose uptake has also shown uPA to indirectly affect PKC activity
[80] which may be a prominent factor in OGD studies.
The use of amiloride selectively attenuated rises in intracellular cal-
cium during reperfusion but not OGD, an effect mimicked by inhibitionof NADPH oxidase. This difference between the two stages is somewhat
surprising. Lack of glucose and associated ATP production and therefore
failure of ion pumps and inﬂuxof calciummay explain ineffectiveness of
uPA and NADPH oxidase suppression in affecting calcium levels during
OGD phase [62]whereas during reperfusionwhen ATP production is re-
established and therefore ion pumps are working the inhibition of uPA
and NADPH oxidase may be more apparent.
The relationship between calcium and uPA or NADPH oxidase re-
mains largely unknown. uPA binding to its receptor has been shown
to increase intracellular calcium concentrations in phagocytes [81] and
stimulate production of inositol-1,4,5-triphosphate (IP3) which then
Fig. 9.Amiloride, apocynin, BAPTA-AMand RO-32-0432 reduced the rate of apoptosis. HBMECwere exposed to 4 h OGD (OGD)with orwithout reperfusion (R) in the absence or presence
of inhibitors for uPA (amiloride), NADPHoxidase (apocynin), intracellular calcium (BAPTA-AM) or PKC-α (RO-32-0432). All inhibitors showed a reduced rate of apoptosis duringOGD±R
however the rate remained elevated compared to normoxic cells (A). TUNEL staining showed fewer apoptotic nuclei (dark brown staining) compared to untreated cells (Bar 50 μm, B).
Arrows indicate representative apoptotic nuclei. Data represented as mean ± SEM from n ≥ 4.* P b 0.05 compared to Normoxia. † P b 0.05 compared to respective untreated group.
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NADPH oxidase activation was required for intracellular calcium in-
creases [81–86] and in human endothelial cells, NADPH oxidase in-
creased calcium release via IP3 [84,85].Conversely, other studies have shown that vascular cell adhesion
molecule-1-induced calcium mobilisation is required for NADPH oxi-
dase activity in lymphocytes [87] and that calcium is required for activa-
tion of Nox5, a NADPH oxidase isoform [86]. Similar to studies with
Fig. 10.OGD±R increases stressﬁbre formation. HBMECwere grownon coverslips and exposed to 4 hOGD (OGD)with orwithout reperfusion (R) in the absence or presence of inhibitors
for uPA (amiloride), NADPH oxidase (apocynin), intracellular calcium (BAPTA-AM) or PKC-α (RO-32-0432). Cells targeted with PKC-α siRNA or non-targeting (NT) siRNA were also ex-
posed to the above conditions. Cells were stained with rhodamine phalloidin to visualise F-actin. Cells exposed to OGD±R showed stress ﬁbre formation compared to normoxic cells and
treated cells showed less stress ﬁbre formation compared to untreated cells exposed to OGD ± R (bar 50 μm). Data represented from n ≥ 4.
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activity [88] and oxidative stress [89] in rats, our study showed calcium
chelation completely normalised O2•− levels and NADPH oxidase activi-
ty. Our study further suggests this is in partmediated through PKC since
PKC inhibitionwas shown to also reduce oxidative stress albeit to a less-
er extent indicating that other calcium-dependent mechanisms alsocontribute to oxidative stress and PKC activation is not the only mecha-
nism that induces NADPH oxidase activity and O2•− production. Indeed
other pathologies arising from ischaemia-reperfusion injury including
the excessive release of pro-inﬂammatory cytokine tumour necrosis
factor-α [52] and ROS due to increased mitochondrial calcium levels
[90] can contribute to oxidative stress.
Fig. 11. PKC-α knockdown restores BBB integrity after OGD±R. HBMECandHA co-cultureswere exposed to 4 hOGD (OGD)with orwithout reperfusion (R) in the absence or presence of
BAPTA-AM, an intracellular calcium inhibitor. Co-cultures were also exposed to PMA, a PKC activator± BAPTA-AM. HBMEC targetedwith PKC-α siRNA or NT siRNA in co-culture with HA
were also exposed to the above OGD±R or PMA conditions. Co-cultures exposed to OGD±R reperfusion with BAPTA-AM show higher TEER values and lower EBA and NaF ﬂux volumes
compared to co-cultures exposed to OGD±R alone (A). PKC-α knockdown increases TEER and decreases EBA andNaFﬂux compared to co-cultures exposed toOGD±R alone (D-F). PMA
increases BBB permeability which is normalised with BAPTA-AM and PKC-α knockdown (G-I). Data represented as mean ± SEM from n ≥ 4. * P b 0.05 compared to Normoxia. § P b 0.05
compared to respective 4 hOGD exposed cells. † P b 0.05 compared to respective untreated group. ‡ P b 0.05 compared to respective NT siRNA targeted group.∞ P b 0.05 compared to PMA.
Ψ P b 0.05 compared to PMA with NT siRNA.
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activate each other. This may partly be due to the sensitivity of PKC
for oxidants like O2•− which can modify its N-terminal regulatory do-
mains making it more resistant to autoinhibition [91] and also through
phosphorylation of NADPH oxidase subunits by PKC which increases
the overall activity of the oxidase complex [92,93].The results from this study indicate that abolishing the activity of
one enzymatic target alone is not enough to completely reverse
cell death and that combination therapy may be required. It would
appear that some cell death is inevitable and future experiments
looking at combination therapy and far reaching targets of the enzymes
involved are needed. For example, some studies suggest matrix
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since our previous study has linked matrix metalloproteinase-2 to uPA
and NADPH oxidase activity [33], it is possible that in HBMEC caspase-
3/7 activation is also mediated by matrix metalloproteinase-2. Addi-
tionally in our previous study [33] uPA was shown to operate upstream
to NADPH oxidase and this study now indicates the involvement of PKC
in this relationship.
All the above inhibitors also markedly decreased OGD ± R-evoked
actin polymerisation, revealing that all the components discussed
have a role in cytoskeletal infrastructure which is necessary for mainte-
nance of cell morphology and function. Pathologies capable of affecting
actin redistribution and polymerisation to form stress ﬁbres have been
shown to increase tight junctional permeability [52,95–97]. Also in rat
brain microvascular endothelial cells exposure to OGD ± R induced
ROS formation, caspase-3 activity, stress ﬁbre formation and tight junc-
tion disruption and inhibition of ROS and caspase-3 attenuated BBB
hyperpermeability through protection of tight junctions and the cyto-
skeleton [98].
Prevention of BBB damage during or restoration of the BBB after an
ischaemic stroke is a priority and any potential therapeutic targets
need to be assessed against their ability to do this. Inhibition of uPA
and NADPH oxidase has been shown in a previous study to restore
BBB integrity [33] and in the present study chelation of intracellular cal-
cium and knockdown of PKC-α has also shown this effect. Indeed even
in the presence of PMA, BAPTA-AM and PKC-α siRNA have been shown
to have a beneﬁcial effect indicating themajor role played by intracellu-
lar calcium and PKC-α.
5. Conclusions
This study shows that in HBMEC exposed to OGD±Rmany individ-
ual events occur which ultimately compromise BBB function. Further-
more these events appear to be interlinked in a complex manner. This
study strongly suggests intracellular calcium is a key mediator of BBB
damage during OGD ± R and the mechanism of increased BBB perme-
ability is an increase in HBMEC apoptosis mediated through a reciprocal
PKC-uPA-NADPH oxidase pathwaywhichwarrants exploring in greater
detail for possible therapeutic outcomes. Furthermore although many
studies conducted with calcium channel blockers show neuroprotec-
tion, the results with regards to stroke outcome are inconclusive partly
due to hypotensive effect of these drugs and associated complications.
Therefore studies examining BBB function and intracellular calcium
levels regardless of the source are needed to deﬁne the calcium-
induced mechanism of BBB disruption. Therapeutic interventions
which target buffering of intracellular calcium without affecting blood
pressure are a possible avenue of exploration.
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